Back to search

Virginia Tech

Repurposing a Kinase Inhibitor for Rift Valley Fever Virus: Combating Hepatic and Neurological Disease Through Antiviral and Immunomodulation Strategies

Abstract

dc:description.abstract

Rift Valley fever virus (RVFV) is a mosquito-borne zoonotic pathogen endemic across the African continent. It represents a significant concern to local agriculture, veterinary and human health, also possessing great pandemic risk. Transmission occurs through infected mosquito vectors or direct exposure to contaminated animal tissues and fluids, disproportionately affecting individuals in close contact with livestock. Human infection is typically self-limiting, but severe manifestations include hepatitis, encephalitis, retinitis, and hemorrhagic disease. No approved antiviral therapeutics currently exist for RVFV infection. This dissertation investigated the role of host casein kinase 1 (CK1) in RVFV replication and NF-κB-mediated inflammation. CK1 regulates multiple cellular processes, including cell cycle progression, apoptosis, DNA damage repair, circadian rhythm, and immune signaling, making it a potential host-directed therapeutic target. Human lung, liver, and neural two-dimensional cell culture models were used to evaluate CK1 inhibition with BTX-A51. BTX-A51 treatment significantly reduced NF-κB-associated cytokines and inflammatory enzymes, while also demonstrating antiviral activity in monolayer cultures. Interactions between NF-κB and β-catenin signaling were additionally observed and discussed. These results were further tested in a human induced pluripotent stem cell (hiPSC)-derived cerebral organoid model. Cerebral organoids were permissive to RVFV infection, also exhibiting some NF-κB-mediated inflammation. BTX-A51 treatment attenuated inflammation while preserving interferon-α and β responses, although antiviral effects promoted by drug treatment in two-dimensional systems were not significant in organoids. Collectively, these findings identify CK1 as a potential host-directed target for immunomodulatory treatment of RVFV pathogenesis and support BTX-A51 as a repurposed therapeutic candidate. This work also demonstrates the value of cerebral organoids as translational models that may reduce reliance on animal studies.

Degree

thesis:*
Name thesis:degree_name
Doctor of Philosophy
Level thesis:degree_level
doctoral
Discipline thesis:degree_discipline
Biomedical and Veterinary Sciences
Department dc:contributor.department
Biomedical and Veterinary Sciences
Grantor dc:publisher
Virginia Tech
Year dc:date.issued
2026

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Machado Flor, Rafaela
Chair dc:contributor.committeechair
  • Kehn-Hall, Kylene Wesley
Committee members dc:contributor.committeemember
  • Auguste, Albert Jonathan
  • Weger, James David
  • Duggal, Nisha

Subjects

dc:subject × 4

Rights

dc:rights
Statement dc:rights
  • Creative Commons Attribution 4.0 International
Language dc:language.iso
en

Identifiers

dc:identifier.*
Dc Identifier Other
vt_gsexam:47030

Chain of custody

source
Harvested from
Virginia Tech
Base URL
vtechworks.lib.vt.edu/oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Machado Flor, Rafaela. Repurposing a Kinase Inhibitor for Rift Valley Fever Virus: Combating Hepatic and Neurological Disease Through Antiviral and Immunomodulation Strategies. doctoral thesis, Virginia Tech, 2026. https://hdl.handle.net/10919/143179